To include your compound in the COVID-19 Resource Center, submit it here.

BioChaperone Lispro: Preliminary Phase IIb data

Preliminary data from 37 Type I diabetics in a double-blind, crossover, German Phase IIa trial showed that single doses of 0.1, 0.2 and 0.4 U/kg BioChaperone Lispro dose-proportionally increased total insulin exposure

Read the full 322 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE